Bausch + Lomb Corporation (BLCO)

Compare

17.34

-0.42

(-2.36%)

As of 2:48:43 PM EST. Market Open.

Bausch + Lomb Bolsters Pipeline with Acquisition of Whitecap Biosciences

VAUGHAN, Ontario, January 13, 2025--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced an affiliate has acquired Whitecap Biosciences, LLC, which is currently developing two innovative therapies for potential use in glaucoma and geographic atrophy (GA). The acquisition strengthens Bausch + Lomb’s expanding clinical-stage pipeline.

Business Wire 7 hours ago

BLCO
-2.36%
Bausch + Lomb Launches enVista Aspire™ Intermediate Optimized Monofocal and Toric Intraocular Lenses in the European Union

VAUGHAN, Ontario, January 13, 2025--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the commercial launch of the enVista Aspire monofocal and toric intraocular lenses (IOLs) in the European Union after receiving a CE Mark late last year. enVista Aspire combines novel Intermediate Optimized optics, which are designed for a broader depth of focus*, with the proven benefits of the enVista® platfor

Business Wire 8 hours ago

BLCO
-2.36%
Is Bausch + Lomb (BLCO) the Best Medical Stock to Buy Under $20?

We recently compiled a list of the Best Medical Stocks To Buy Under $20. In this article, we are going to take a look at where Bausch + Lomb Corporation (NYSE:BLCO) stands against the other best medical stocks under $20. The medical industry plays a crucial role in ensuring the health and safety of populations. […]

Insider Monkey yesterday

BHC
-4.70%
BLCO
-2.36%
Bausch + Lomb and Glaucoma Research Foundation Launch Second Annual "Faces of Glaucoma" Campaign and Fundraising Challenge

VAUGHAN, Ontario, January 07, 2025--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, and Glaucoma Research Foundation (GRF), a national nonprofit organization dedicated to curing glaucoma, are launching the second annual "Faces of Glaucoma" campaign. The campaign, which will highlight diverse patient stories and raise awareness of the second leading cause of blindness worldwide,1 will take place throughout Glau

Business Wire 6 days ago

BLCO
-2.36%
Bausch + Lomb price target lowered to $22 from $25 at Evercore ISI

Evercore ISI lowered the firm’s price target on Bausch + Lomb (BLCO) to $22 from $25 and keeps an Outperform rating on the shares. In the firm’s 2025 outlook note for MedTech, Life Science Tools and Diagnostics, the analyst argues that FY25 guides from the life science tools group are likely to be conservative on China and Pharma, while in MedTech the firm contends that “healthy” utilization trends and a margin expansion thesis support the group. Published first on TheFly – the ultimate source f

TipRanks 10 days ago

BLCO
-2.36%
Bausch + Lomb to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

VAUGHAN, Ontario, January 02, 2025--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that Chairman and CEO Brent Saunders, Chief Financial Officer Sam Eldessouky and Chief Medical Officer and Head of Research & Development Yehia Hashad, M.D., will participate in a company presentation at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025, at 11:15 a.m. PT (2:15 p.m. ET

Business Wire 11 days ago

BLCO
-2.36%
BofA rates Bausch & Lomb ‘underperform’ with lower buyout chances

Investing.com -- Bank of America has reinstated coverage of Bausch + Lomb Corp (NYSE:BLCO) with an "underperform" rating and a price target of $18, amid reduced prospects of a private equity buyout.

Investing.com last month

BLCO
-2.36%
BX
Bausch + Lomb Responds to Rumors of a Potential Sale

VAUGHAN, Ontario, December 12, 2024--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, issued the following statement in response to a request from the Canadian Investment Regulatory Organization (CIRO):

Business Wire last month

BLCO
-2.36%
Bausch + Lomb Acquires Elios Vision, Significantly Enhances Glaucoma Treatment Capabilities

VAUGHAN, Ontario, December 11, 2024--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that an affiliate has acquired Elios Vision, Inc., developer of the ELIOS™ procedure, the first clinically validated, minimally invasive glaucoma surgery (MIGS) procedure using an excimer laser. The acquisition unlocks new opportunities to treat glaucoma effectively in conjunction with cataract surgery without

Business Wire last month

BLCO
-2.36%
Bausch & Lomb Corporation (BLCO)-A Bull Case Theory

In this article, we’ll summarize a bullish thesis posted on VIC covering Bausch & Lomb Corporation (BLCO) in late July when BLCO stock was trading at $15.83. Currently, BLCO stock is trading at $19.68, which is near its 52-week high of $21.69. So, BLCO stock has gained over 24% since the publication of this thesis. […]

Insider Monkey last month

BLCO
-2.36%
Bausch + Lomb Reports More Than 94 Million Units of Contact Lenses, Lens Care and Eye Care Materials Collected Through ONE By ONE and Biotrue® Eye Care Recycling Programs

VAUGHAN, Ontario, November 14, 2024--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced its exclusive ONE by ONE Recycling and Biotrue Eye Care Recycling programs have collected a total of 94,119,275 units*, or 569,743 pounds, of used contact lenses, eye care and lens care materials in the United States. That’s equivalent to the weight of roughly 690 polar bears1.

Business Wire last month

BLCO
-2.36%
Bausch + Lomb Third Quarter 2024 Earnings: Beats Expectations

Bausch + Lomb ( NYSE:BLCO ) Third Quarter 2024 Results Key Financial Results Revenue: US$1.20b (up 19% from 3Q 2023...

Simply Wall St. 2 months ago

BLCO
-2.36%
Bausch & Lomb Corp (BLCO) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and ...

Bausch & Lomb Corp (BLCO) reports robust 19% revenue growth and raises full-year guidance amid strategic investments and market expansion.

GuruFocus.com 2 months ago

BLCO
-2.36%
Bausch + Lomb Announces Third-Quarter 2024 Results

VAUGHAN, Ontario, October 30, 2024--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced its third-quarter 2024 financial results.

Business Wire 2 months ago

BLCO
-2.36%
Bausch + Lomb price target raised to $23 from $20 at RBC Capital

RBC Capital analyst Douglas Miehm raised the firm’s price target on Bausch + Lomb (BLCO) to $23 from $20 and keeps an Outperform rating on the shares ahead of its Q3 results. The firm is incorporating a sale scenario into its new price target with several media articles over the last month indicating that the company is working with advisers to test interest from potential buyers, the analyst tells investors in a research note. Published first on TheFly – the ultimate source for real-time, marke

TipRanks 2 months ago

BLCO
-2.36%
Bausch + Lomb Receives FDA Approval for enVista® Envy™ Full Range of Vision Intraocular Lens

VAUGHAN, Ontario, October 14, 2024--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that the U.S. Food and Drug Administration has approved the enVista® Envy™ full range of vision intraocular lens (IOL), which offers a continuous range of vision with excellent dysphotopsia tolerance on the widely used enVista IOL platform.

Business Wire 2 months ago

BLCO
-2.36%
Bausch + Lomb Will Release Third-Quarter 2024 Financial Results on October 30

VAUGHAN, Ontario, October 09, 2024--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, will release its third-quarter 2024 financial results on Wednesday, October 30, 2024. Bausch + Lomb will host a conference call and live webcast at 8 a.m. ET to discuss the results and provide a business update. All materials will be made available on the Investor Relations section of the Bausch + Lomb website prior to the star

Business Wire 3 months ago

BLCO
-2.36%
Bausch + Lomb price target raised to $19 from $17 at Evercore ISI

Evercore ISI raised the firm’s price target on Bausch + Lomb to $19 from $17 and keeps an In Line rating on the shares. In MedTech, utilization remains positive into Q3 and the capex outlook into the next year remains “healthy,” says Evercore. In life science tools, bioprocess trends for are on track for improvement in the second half, but the debate is around the instrument outlook and China stimulus given the recent run in stocks in the space, the analyst tells investors in MedTech and Tools Q

TipRanks 3 months ago

BLCO
-2.36%
Bausch + Lomb Launches Opal™ Digital Marketplace in the United States

VAUGHAN, Ontario, October 01, 2024--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the U.S. launch of Opal, a digital e-commerce marketplace. Designed to help maximize efficiencies for eye care practices while enhancing the patient experience, Opal provides a streamlined ordering process for Bausch + Lomb contact lenses, with select Bausch + Lomb over-the-counter products to be added in the co

Business Wire 3 months ago

BLCO
-2.36%
Bausch + Lomb explores sale amid parent company's debt woes - report

Bausch + Lomb (NYSE:BLCO) is exploring a potential sale as part of an effort to resolve issues related to its separation from parent company Bausch Health, which is burdened with significant debt, as per a Financial Times report. The move has faced opposition from lenders, including Apollo Global Management (NYSE:APO). “This (sale) makes sense to us given the steep valuation discount between BLCO and its closest eye care peers,” said analysts from Wells Fargo in a note.

Investing.com 3 months ago

BHC
-4.70%
BLCO
-2.36%

Performance Overview

Return	BLCO	S&P/TSX Composite index
YTD	-2.53%	-0.29%
1-Year	+13.93%	+16.96%
3-Year	-6.27%	+14.75%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Bausch + Lomb Corporation (BLCO)

Bausch + Lomb Bolsters Pipeline with Acquisition of Whitecap Biosciences

Bausch + Lomb Launches enVista Aspire™ Intermediate Optimized Monofocal and Toric Intraocular Lenses in the European Union

Is Bausch + Lomb (BLCO) the Best Medical Stock to Buy Under $20?

Bausch + Lomb and Glaucoma Research Foundation Launch Second Annual "Faces of Glaucoma" Campaign and Fundraising Challenge

Bausch + Lomb price target lowered to $22 from $25 at Evercore ISI

Bausch + Lomb to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

BofA rates Bausch & Lomb ‘underperform’ with lower buyout chances

Bausch + Lomb Responds to Rumors of a Potential Sale

Bausch + Lomb Acquires Elios Vision, Significantly Enhances Glaucoma Treatment Capabilities

Bausch & Lomb Corporation (BLCO)-A Bull Case Theory

Bausch + Lomb Reports More Than 94 Million Units of Contact Lenses, Lens Care and Eye Care Materials Collected Through ONE By ONE and Biotrue® Eye Care Recycling Programs

Bausch + Lomb Third Quarter 2024 Earnings: Beats Expectations

Bausch & Lomb Corp (BLCO) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and ...

Bausch + Lomb Announces Third-Quarter 2024 Results

Bausch + Lomb price target raised to $23 from $20 at RBC Capital

Bausch + Lomb Receives FDA Approval for enVista® Envy™ Full Range of Vision Intraocular Lens

Bausch + Lomb Will Release Third-Quarter 2024 Financial Results on October 30

Bausch + Lomb price target raised to $19 from $17 at Evercore ISI

Bausch + Lomb Launches Opal™ Digital Marketplace in the United States

Bausch + Lomb explores sale amid parent company's debt woes - report

Performance Overview